News
Google News
Full Coverage

Axsome Therapeutics receives FDA approval for Auvelity

Top news

Investor's Business Daily

Axsome Hits Record High On Alzheimer's Agitation Approval

By Allison Gatlin
Medscape

FDA OKs First Non-Antipsychotic for Alzheimer’s Agitation

By Liz Borreli
Psychiatric Times

FDA Approves Auvelity for Treatment of Agitation in Alzheimer Disease

By Leah Kuntz
Neurology Live

FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation

By Marco Meglio

All coverage

Fierce Pharma

Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation

By Kevin Dunleavy
statnews.com

Axsome wins FDA nod for Alzheimer’s agitation

By Meghana Keshavan
Reuters

US FDA approves Axsome's drug for Alzheimer's-related agitation

By Mariam E Sunny & Kamal Choudhury
Being Patient

FDA Approves New Drug for Alzheimer’s Agitation

By Simon Spichak
The American Journal of Managed Care

FDA Approves Dextromethorphan-Bupropion for Agitation Due to Alzheimer Disease

qz.com

FDA approves first non-antipsychotic drug for Alzheimer's agitation, driving Axsome shares up 12%

By Colleen Cabili
RAPS.org

Recon: FDA approves Axsome drug to treat agitation in Alzheimer’s patients; HHS appeals ruling on Kennedy’s vaccine policies

BioWorld News

Axsome’s Auvelity cleared for large Alzheimer’s agitation market

By Karen Carey
pharmaphorum

Axsome breaks new ground in Alzheimer's with Auvelity OK

Pharmaceutical Executive

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

By Nicholas I Jacobus
Clinical Trials Arena

Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation

Endpoints News

FDA approves Auvelity for Alzheimer's agitation; Esperion goes private in $1.1B deal

Stocktwits

AXSM Stock Clocks Best Day In About 4 Months On FDA Greenlight For Alzheimer’s Drug

By Anan Ashraf
Investing.com Nigeria

Axsome earnings on deck after Alzheimer’s drug approval By Investing.com

Conexiant

FDA Approves Auvelity for Agitation in Alzheimer’s Disease

By Kathryn Wighton
Pharmaceutical Technology

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

TradingView

AXSM: FDA approved AUVELITY for agitation in Alzheimer's, offering a new, effective treatment option

Seeking Alpha

Axsome wins FDA label expansion for Auvelity (AXSM:NASDAQ)

By Dulan Lokuwithana
GuruFocus

Axsome Therapeutics Receives FDA Approval for AXS-05 in Alzheimer's Treatment

Patient Care Online

FDA Approves First Non-Antipsychotic Treatment for Alzheimer Agitation

The Pharma Letter

FDA clears Axsome’s Auvelity for Alzheimer’s agitation

Pharmacy Times

FDA Approves First Non-Antipsychotic Treatment for Agitation Associated With Alzheimer Disease

By Luke Halpern
FirstWord Pharma

Axsome's Auvelity is first non-antipsychotic cleared in US for Alzheimer's agitation

By Elizabeth Eaton
BioSpace

Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation

By Tristan Cesar Manalac
marketscreener.com

US FDA approves Axsome's drug for Alzheimer's-related agitation

TipRanks

Axsome Therapeutics Stock Surges on Surprise FDA Win

Medical Dialogues

FDA approves first non psychotic Auvelity for Agitation in Alzheimer’s Dementia

By Kamal Kant Kohli
MarketBeat

Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June

RTTNews

Axsome Therapeutics Nears FDA Decision On Alzheimer's Agitation Therapy

Benzinga

Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

By Vandana Singh
Quiver Quantitative

Axsome Therapeutics Announces FDA Approval of AUVELITY for Agitation Associated with Alzheimer’s Disease

PharmaLive

Axsome gets FDA approval for first non-antipsychotic drug to treat agitation associated with Alzheimer's dementia

Yahoo Finance

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Stocktwits

AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week

Yahoo Finance

Does Axsome (AXSM) Unlock a New CNS Franchise with AUVELITY’s Alzheimer’s Agitation Approval?

Investing.com Canada

Axsome earnings on deck after Alzheimer’s drug approval By Investing.com

Psychiatric Times

AXS-05 Approval for Agitation in Alzheimer Disease: Notes From John J. Miller, MD

By John J Miller
Psychiatric Times

The Approval of Auvelity, the Second Treatment for Alzheimer Disease Agitation

By Dr. Rajesh Tampi
KELO-AM

US FDA approves Axsome’s drug for Alzheimer’s-related agitation

By Kamal Choudhury, Mariam E Sunny & Leroy Leo
KFGO

US FDA approves Axsome’s drug for Alzheimer’s-related agitation

By Kamal Choudhury & Mariam E Sunny
WKZO

US FDA approves Axsome’s drug for Alzheimer’s-related agitation

By Kamal Choudhury, Mariam E Sunny & Leroy Leo
Investing.com Nigeria

Axsome Therapeutics stock surges on FDA approval for Alzheimer’s By Investing.com

By Louis Juricic
Investing.com Canada

Axsome Therapeutics stock surges on FDA approval for Alzheimer’s By Investing.com

By Louis Juricic
TipRanks

Axsome Wins FDA Nod for Alzheimer’s Agitation Drug

Yahoo! Finance Canada

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

Investing.com

Axsome Therapeutics stock surges on FDA approval for Alzheimer’s

By Louis Juricic
GlobeNewswire

Axsome Therapeutics Announces FDA Approval of AUVELITY®

Investing.com South Africa

Axsome Therapeutics stock surges on FDA approval for Alzheimer’s By Investing.com

By Louis Juricic
Search
Clear search
Close search
Google apps
Main menu